LimmaTech Awarded FDA Fast Track Designation for Vaccine Candidate ...
LimmaTech Biologics AG received FDA Fast Track designation for LBT-SA7, a vaccine targeting Staphylococcus aureus infections, aiming to expedite its development. LBT-SA7, designed to prevent SSTIs by neutralizing toxins, will undergo Phase 1 trials in the U.S. with results expected in 2025.
Reference News
LimmaTech Awarded FDA Fast Track Designation for Vaccine Candidate ...
LimmaTech Biologics AG received FDA Fast Track designation for LBT-SA7, a vaccine targeting Staphylococcus aureus infections, aiming to expedite its development. LBT-SA7, designed to prevent SSTIs by neutralizing toxins, will undergo Phase 1 trials in the U.S. with results expected in 2025.